Two new drugs for Parkinson's just hit the market

November 1997

Two new drugs for Parkinson's just hit the market...ropinirole (Requip, SmithKline Beecham) and tolcapone (Tasmar, Roche).

Requip is a second-generation dopamine agonist.

It's more selective for dopamine than the first generation agonists...Permax (pergolide) and Parlodel (bromocriptine).

Practical advice for a better career, with unlimited access to CE

Pharmacy Technician's Letter Canada includes:

12 issues every year, with brief articles about new meds and hot topics
120+ CE courses, including the popular CE-in-the-Letter
Helpful, in-depth Technician Tutorials
Access to the entire archive

Subscribe Today!

Already a subscriber? Log in

Volume pricing available. Get a quote

Table of Contents

New technology is helping pharmacists provide pharmaceutical care
Parkinson Disease Two new drugs for Parkinson's just hit the market
Parkinson Disease Tasmar is the first in a new class
Osteoporosis Fosamax (alendronate) to PREVENT osteoporosis in postmenopausal women
Hepatitis C lamivudine (3TC) for chronic hepatitis B
Hepatitis C more attention these days on hepatitis C
Cholesterol Cardiem, a new supplement to lower cholesterol
Neurology & Pain Copaxone (glatiramer acetate) for multiple sclerosis
Neurology & Pain new antiepileptic, Gabitril (tiagabine)
Women's Health treating severe premenstrual symptoms with SSRIs
which vit E supplements are best
asking about alpha lipoic acid (thioctic acid)
Hypertension new angiotensin II antagonists
Famvir and Valtrex for long-term therapy
Combivir, the first combo tablet for HIV
The FDA will approve thalidomide
metered-dose inhalers (MDIs) instead of a nebulizer to treat ACUTE asthma or COPD
Practice You'll soon see ads for Zantac 75